Samabriva Opens New Biomanufacturing Facility in Belgium

French biotechnology company Samabriva has opened a new 1,400 m² biomanufacturing facility in Liege, Belgium, at the heart of European’s biotech valley—strengthening its position as a leading player in the region’s thriving biomanufacturing ecosystem.
 
This multi-million Euros investment is designed to provide industrial-scale production of high-value natural molecules used in the manufacture of pharmaceutical products. Equipped with Samabriva’s proprietary bioreactors, which have been specifically designed to maximize production in hairy root culture, the facility will enhance efficiency and output.
 
This announcement represents the next step in Samabriva’s growth strategy, marking the transition to industrial production following a decade of research and development. Phase one of the facility will be operational by Q1 2025 to meet the demands of the company’s first commercial international customers.
 
In addition to providing advanced manufacturing, the facility will create several new jobs across bioproduction, analytics, and quality assurance, contributing to global economic growth. It will also provide customers with full control over the biomanufacturing process, offering a cost-effective and sustainable alternative to open-field production.
 
Bertrand Duquesne, COO and QP for Samabriva Biomanufacturing, said: “We are delighted to be implementing the high potential manufacturing platform that Samabriva has been developing over the last ten years on an industrial scale. The platform will enable GMP quality production of molecules of interest for our current and future customers.”